Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer - PubMed
5 hours ago
- #Chronic inflammation
- #Hydrogel therapy
- #Immunotherapy
- Chronic inflammation in tumors weakens immunotherapy by promoting protumor immune cell communication.
- TRANS hydrogel is developed to shift protumor inflammation to immunosurveillance by restoring myeloid-T cell crosstalk.
- TRANS releases celecoxib (CXB) to inhibit the COX-2/PGE2 pathway, reprogramming tumor-associated macrophages and reducing inflammation.
- TRANS includes Flt-3L and α-CD137 to recruit cDC1 and revitalize T cells, enhancing immunosurveillance.
- TRANS shows high efficacy in inhibiting primary and secondary colorectal tumors (87.50% and 88.74%) and reduces metastases.
- Single-cell RNA sequencing reveals TRANS optimizes myeloid-T cell crosstalk via CXCL9/10-CXCR3/DPP4 pathways.
- Combining TRANS with immune checkpoint inhibitors improves colorectal cancer control.
- TRANS generates antitumor immune memory, resisting tumor rechallenge.